Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

In most countries, healthcare service budgets are not likely to support the current explosion
in the cost of new oncology drugs. Repurposing the large arsenal of approved, non …

Background This guideline addressed VTE prevention in hospitalized medical patients,
outpatients with cancer, the chronically immobilized, long-distance travelers, and those with …

This article discusses the prevention of venous thromboembolism (VTE) and is part of the
Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence …

Background Clinical trials are needed to assess the clinical benefit of antithrombotic
prophylaxis in patients with cancer who are receiving chemotherapy, since these patients …

Purpose Advanced pancreatic cancer (APC), in addition to its high mortality, accounts for the
highest rates of venous thromboembolic events (VTEs). Enoxaparin, a low–molecular weight …

Purpose To develop guideline recommendations for the use of anticoagulation in the
prevention and treatment of venous thromboembolism (VTE) in patients with cancer …

Venous thromboembolism occurs commonly in patients with cancer. The pathogenetic
mechanisms of thrombosis involve a complex interaction between tumour cells, the …

Background Venous thromboembolism (VTE) often complicates the clinical course of
cancer. The risk is further increased by chemotherapy, but the trade‐off between safety and …

Cancer patients are at high risk for venous thromboembolism (VTE). Laboratory parameters
with a predictive value for VTE could help stratify patients into high-or low-risk groups. The …